Article Sidebar

pdf
Date Published: 01/07/2025
Abstract Views: 425
Views pdf: 194
DOI: https://doi.org/10.51298/vmj.v551i3.14682
Issue
Vol. 551 No. 3 (2025)
Section
Các bài báo
How to Cite
Hoàng Thị, H., & Phạm Cẩm, P. (2025). THE RESULTS OF GEFTINIB AS THE FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS HARBORING EGFR MUTATIONS. Vietnam Medical Journal, 551(3). https://doi.org/10.51298/vmj.v551i3.14682

THE RESULTS OF GEFTINIB AS THE FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS HARBORING EGFR MUTATIONS

Hà Hoàng Thị, Phương Phạm Cẩm

Main Article Content

Abstract

Objectives: To describe some clinical and paraclinical features of advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations. Evaluation the treatment results of gefitinib as the first-line treatment. Subjects and methods: A retrospective descriptive study on 63 advanced NSCLC patients harboring EGFR mutations who received gefitinib as the first-line treatment at Thanh Hoa Oncology Hospital from January 2021 to May 2024. Results: The average age was 64.4. The male/female ratio was 1.17/1. The mutation rates of exon 19 and exon 21 were 57.1% and 34.9%, respectively. 85.7% of patients responded partially. The disease control rate was 93.7%. Overall survival (OS): 35 ± 4.2 months, progression free survival (PFS): 14 ± 1.9 months Conclusions: Gefitinib as the first-line treatment achieved high outcomes.

Article Details

Keywords

non-small cell lung cancer, EGFR mutations, gefitinib

References

1. Laversanne, M., Frick, C. Arnold, M., Rousset, V., Foreman, D. A., Bray, F. (2024). Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN. Cancer Epidemiology, 93, 102693. https:// doi.org/10.1016/j.canep. 2024.102693
2. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015;10(9):1243-1260.
3. Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299-311.
4. Kuan F, Kuo L, Chen M. et al. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. Br J Cancer. 2015; 113, 1519–1528.
5. Maemondo M, Inoue A, Kobayashi K et al (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25): 2380-2388.
6. Mitsudomi T, Morita S, Yatabe Y et al (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2): 121-128.
7. Đỗ Thị Phương Chung (2020). Đánh giá kết quả điều trị Gefitinib trong ung thư phổi không tế bào nhỏ tái phát, di căn. Luận án tiến sỹ y học,Đại học Y Hà Nội.
8. Phạm Văn Luận (2020).Điều trị ung thư biểu mô tuyến của phổi gia đoạn tiến xa đột biến gen EGFR dương tính bằng Gefitinib.Tạp chí y dược lâm sàng 108, số 4 (15), 30-37.
9. Phạm Văn Trường (2013). Đánh giá hiệu quả hóa trị phác đồ Vinorelbine - Cisplatin trong ung thư phổi không tế bào nhỏ giai đoạn IIIB-IV tại Bệnh viện K, Luận văn thạc sĩ Y học, Đại học Y Hà Nội.